Close Menu

NEW YORK – Qiagen said on Wednesday that it has forged a collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic to identify patients with squamous cell head and neck cancer caused by specific human papillomavirus (HPV) infections, who may be eligible for BioNTech's investigational cancer treatment BNT113.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.